Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 6/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | FOS | P01100 | 1/20 | 0.54 |
| ▸ | JUN | P05412 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
| ▸ | RELA | Q04206 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28094563 | 0.83 | SYK (0.41) | SYKMAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL20909971 | 0.82 | SYK (0.41) | SYKMAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL28496543 | 0.80 | SYK (0.67) | SYKMAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL12197611 | 0.79 | LRRK2 (0.42) | SYKMAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL1313596 | 0.79 | SYK (0.79) | SYKMAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL24774356 | 0.79 | MAPT (0.65) | SYKMAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL4851406 | 0.79 | SYK (0.60) | SYKMAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL29545771 | 0.78 | ALDH1A1 (0.70) | SYKMAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL1521842 | 0.78 | ALDH1A1 (0.70) | SYKMAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL14633390 | 0.77 | MEN1 (0.54) | SYKMAPTALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112079830-B | Inhibitor containing fused ring derivative, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-12-22 | — | — | CN | disclosed |
| EP-3733184-B1 | PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3733184-B1 | PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-112079830-A | Fused ring-containing derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2020-12-15 | — | — | CN | disclosed |
| EP-3733184-A1 | PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Icahn School of Medicine at Mount Sinai (US) | 2020-11-04 | — | — | EP | disclosed |
| EP-3733184-A1 | PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Icahn School of Medicine at Mount Sinai (US) | 2020-11-04 | — | — | EP | disclosed |
| EP-2968331-B1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-07-01 | — | — | EP | disclosed |
| EP-2968331-B1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-07-01 | — | — | EP | disclosed |
| US-9815847-B2 | Pyrimidine compounds as kinase inhibitors | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815847-B2 | Pyrimidine compounds as kinase inhibitors | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815847-B2 | Pyrimidine compounds as kinase inhibitors | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160122361-A1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2016-05-05 | — | — | US | disclosed |
| US-20160122361-A1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2016-05-05 | — | — | US | disclosed |
| US-20160122361-A1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2016-05-05 | — | — | US | disclosed |
| WO-2014151682-A1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2014-09-25 | — | — | WO | disclosed |
| US-8575179-B2 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2013-11-05 | — | — | US | disclosed |
| US-8575179-B2 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2013-11-05 | — | — | US | disclosed |
| EP-2376494-A1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVES | MSD K.K. (JP) | 2011-10-19 | — | — | EP | disclosed |
| US-20110245229-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | MSD K.K. (JP) | 2011-10-06 | — | — | US | disclosed |
| WO-2010067888-A1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245229-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | WEE2, WEE1, CDKL1 | SYK 2126/4885MAPT 4346/4885ALDH1A1 871/4885 |
| US-20160122361-A1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | DCK, TK1, DTYMK | SYK 1391/4885MAPT 2299/4885ALDH1A1 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.